Shopping Cart 0
Cart Subtotal
USD 0

Neurovance Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Neurovance Inc (Neurovance) is a clinical stage neuroscience focused company that develops centanafadine (CTN) SR for adult and pediatric Attention Deficit Hyperactivity Disorder (ADHD). CTN, formerly EB-1020, is a novel triple reuptake inhibitor that acts as a functional hybrid with activity intermediate between stimulants and non-stimulants; and increases dopamine activity. ADHD is the common childhood disorders that has three subtypes-hyperactive-impulsive; inattentive and combined hyperactive-impulsive and inattentive. The company received funds from various investors that include Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, and State of Wisconsin Investment Board (SWIB). Neurovance is headquartered in Cambridge, Massachusetts, the US.

Neurovance Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Neurovance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Neurovance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Neurovance Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Neurovance Raises USD0.6 Million in Venture Financing 10

Neurovance Raises Additional USD1.5 Million in Venture Financing 10

Neurovance Raises Additional USD5 Million Financing 11

Neurovance Raises USD1 Million in Financing Round 11

Neurovance Raises Additional USD5.5 Million in Venture Financing 12

Neurovance Raises Additional USD4 Million in Venture Financing 13

Neurovance Raises US$3.3 Million In Extended Series A1 Financing 14

Neurovance Raises USD3 Million in Venture Financing 15

Neurovance Raises US$6 Million In Series A1 Financing 15

Neurovance Raises Additional US$0.32 Million In Venture Financing 17

Acquisition 17

Otsuka Pharma to Acquire Neurovance 17

Neurovance Inc-Key Competitors 19

Key Employees 20

Locations And Subsidiaries 21

Head Office 21

Recent Developments 22

Corporate Communications 22

Dec 14, 2016: Neurovance Announces the Appointment of Brian Goff as Chief Operating Officer as the Company Prepares for the Next Stage of Growth and Development 22

Product News 23

01/07/2016: Neurovance Appoints Jeff Bailey to Chair Its Board of Directors 23

Clinical Trials 24

Jan 07, 2016: Neurovance Announces Series of Three Clinical Trials to Support Advanced Development of Centanafadine (CTN) in Adult ADHD 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

Neurovance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Neurovance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8


List Of Table

List of Tables

Neurovance Inc, Pharmaceuticals & Healthcare, Key Facts 1

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Neurovance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Neurovance Inc, Deals By Therapy Area, 2011 to YTD 2017 8

Neurovance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Neurovance Raises USD0.6 Million in Venture Financing 10

Neurovance Raises Additional USD1.5 Million in Venture Financing 10

Neurovance Raises Additional USD5 Million Financing 11

Neurovance Raises USD1 Million in Financing Round 11

Neurovance Raises Additional USD5.5 Million in Venture Financing 12

Neurovance Raises Additional USD4 Million in Venture Financing 13

Neurovance Raises US$3.3 Million In Extended Series A1 Financing 14

Neurovance Raises USD3 Million in Venture Financing 15

Neurovance Raises US$6 Million In Series A1 Financing 15

Neurovance Raises Additional US$0.32 Million In Venture Financing 17

Otsuka Pharma to Acquire Neurovance 17

Neurovance Inc, Key Competitors 19

Neurovance Inc, Key Employees 20

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Neurovance Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Neurovance Inc (Neurovance) is a clinical stage neuroscience focused company that develops centanafadine (CTN) SR for adult and pediatric Attention Deficit Hyperactivity Disorder (ADHD). CTN, formerly EB-1020, is a novel triple reuptake inhibitor that acts as a functional hybrid with activity intermediate between stimulants and non-stimulants; and increases dopamine activity. ADHD is the common childhood disorders that has three subtypes-hyperactive-impulsive; inattentive and combined hyperactive-impulsive and inattentive. The company received funds from various investors that include Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, and State of Wisconsin Investment Board (SWIB). Neurovance is headquartered in Cambridge, Massachusetts, the US.

Neurovance Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Neurovance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Neurovance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Neurovance Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Neurovance Raises USD0.6 Million in Venture Financing 10

Neurovance Raises Additional USD1.5 Million in Venture Financing 10

Neurovance Raises Additional USD5 Million Financing 11

Neurovance Raises USD1 Million in Financing Round 11

Neurovance Raises Additional USD5.5 Million in Venture Financing 12

Neurovance Raises Additional USD4 Million in Venture Financing 13

Neurovance Raises US$3.3 Million In Extended Series A1 Financing 14

Neurovance Raises USD3 Million in Venture Financing 15

Neurovance Raises US$6 Million In Series A1 Financing 15

Neurovance Raises Additional US$0.32 Million In Venture Financing 17

Acquisition 17

Otsuka Pharma to Acquire Neurovance 17

Neurovance Inc-Key Competitors 19

Key Employees 20

Locations And Subsidiaries 21

Head Office 21

Recent Developments 22

Corporate Communications 22

Dec 14, 2016: Neurovance Announces the Appointment of Brian Goff as Chief Operating Officer as the Company Prepares for the Next Stage of Growth and Development 22

Product News 23

01/07/2016: Neurovance Appoints Jeff Bailey to Chair Its Board of Directors 23

Clinical Trials 24

Jan 07, 2016: Neurovance Announces Series of Three Clinical Trials to Support Advanced Development of Centanafadine (CTN) in Adult ADHD 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

Neurovance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Neurovance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8


List Of Table

List of Tables

Neurovance Inc, Pharmaceuticals & Healthcare, Key Facts 1

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Neurovance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Neurovance Inc, Deals By Therapy Area, 2011 to YTD 2017 8

Neurovance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Neurovance Raises USD0.6 Million in Venture Financing 10

Neurovance Raises Additional USD1.5 Million in Venture Financing 10

Neurovance Raises Additional USD5 Million Financing 11

Neurovance Raises USD1 Million in Financing Round 11

Neurovance Raises Additional USD5.5 Million in Venture Financing 12

Neurovance Raises Additional USD4 Million in Venture Financing 13

Neurovance Raises US$3.3 Million In Extended Series A1 Financing 14

Neurovance Raises USD3 Million in Venture Financing 15

Neurovance Raises US$6 Million In Series A1 Financing 15

Neurovance Raises Additional US$0.32 Million In Venture Financing 17

Otsuka Pharma to Acquire Neurovance 17

Neurovance Inc, Key Competitors 19

Neurovance Inc, Key Employees 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Neurovance Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.